Buscar
Scinai Immunotherapeutics Ltd
SCNIAñadir a la lista de seguimiento
0.239USD
+0.009+3.95%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
829.60KCap. mercado
PérdidaP/E TTM
Más Datos de Scinai Immunotherapeutics Ltd Compañía
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Información de Scinai Immunotherapeutics Ltd
Símbolo de cotizaciónSCNI
Nombre de la empresaScinai Immunotherapeutics Ltd
Fecha de salida a bolsaJun 07, 2007
Director ejecutivoReichman (Amir)
Número de empleados31
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 07
DirecciónJerusalem Biopark, 2Nd Floor
CiudadJERUSALEM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal00000
Teléfono97289302529
Sitio Webhttps://www.scinai.com/
Símbolo de cotizaciónSCNI
Fecha de salida a bolsaJun 07, 2007
Director ejecutivoReichman (Amir)
Ejecutivos de Scinai Immunotherapeutics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
19.51K
+58.60%
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
4.87K
+73.89%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
1.18K
+76.63%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-36.00%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
--
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
19.51K
+58.60%
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
4.87K
+73.89%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
1.18K
+76.63%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-36.00%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Scinai Immunotherapeutics Ltd?
Los cinco principales accionistas de Scinai Immunotherapeutics Ltd son: Mr. Mark S. Germain
¿Cuántas instituciones poseen acciones de Scinai Immunotherapeutics Ltd (SCNI)?
A fecha de 2026Q1, 23 instituciones poseen acciones de Scinai Immunotherapeutics Ltd, con un valor de mercado combinado de aproximadamente 179.71K, lo que representa el 5.08% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 33890.00.